Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Research and Clinical Diagnostic Tests and Controls
  4. Flu and Virus Testing
  5. COVID Testing Kits
  6. B256084

BD Veritor™ Combo Pack: 2 SARS-CoV-2 Kits and 1 Analyzer

Catalog No. B256084 Shop All BD Diagnostic Systems Products
Change view
Click to view available options
Quantity:
60 Tests, 1 Analyzer
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
B256084 60 Tests, 1 Analyzer
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. B256084 Supplier BD Veritor™ Supplier No. 256084
Only null left
Add to Cart
Add to Cart

Description

Promotional kit for rapid detection of SARS-CoV-2 (COVID-19) in 15 minutes

  • Get rapid, reliable SARS-CoV-2 results in just 15 minutes
  • Dual anterior nares sample collection
  • Clear, digitally displayed results that detect positives not recognized by the unaided eye.
  • Virtual SKU contains QTY 2 of BD Veritor™ System for Rapid Detection of SARS-CoV-2 (256082) and QTY 1 of BD Veritor™ Plus Analyzer (256066)
  • Contains 60 tests and 1 instrument
TRUSTED_SUSTAINABILITY

Specifications

Certifications/Compliance Certificate of Conformance
Content And Storage 2°C to 30°C
Control Sets SARS+, SARS- included
CPT Code 87426
CE Marker No
Clia Complexity Waived
Detectable Analytes SARS-CoV-2
DoA Calibrators No
Sample Type Dual Anterior Nares
Sensitivity 84%
Type Rapid Antigen
For Use With (Application) Laterial Flow Immunoassay
For Use With (Equipment) BD Veritor Plus Analyzer (256066) Included in This Promotional Kit
Quantity 60 Tests, 1 Analyzer
Specificity 1
Test Time 15 min.
Form Liquid
Show More Show Less

*The BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 is intended for the qualitative detection of SARS-CoV-2 nucleocapsid antigens in direct anterior nasal swabs from individuals who are either suspected of COVID-19 by their health care provider within the first five days of the onset of symptoms, or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests.

  • This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories.
  • This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens.
  • This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.